Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Maria Roussou

Showing results (41-50 of 71) with videos related to

Pageof 8
Sort By:
Leukemia & Lymphoma|January 11, 2019
Vulnerability variables among octogenerian myeloma patients: a single-center analysis of 110 patientsMaria Gavriatopoulou, Despina Fotiou, Ursula Koloventzou, et al.
Diseases (Basel, Switzerland)|September 27, 2023
Tixagevimab/Cilgavimab as Pre-Exposure Prophylaxis against COVID-19 for Multiple Myeloma Patients: A Prospective Study in the Omicron EraIoannis Ntanasis-Stathopoulos, Charalampos Filippatos, Maria Gavriatopoulou, et al.
Journal of Clinical Medicine|October 7, 2020
Circulating Soluble Urokinase-Type Plasminogen Activator Receptor Levels Reflect Renal Function in Newly Diagnosed Patients with Multiple Myeloma Treated with Bortezomib-Based InductionEvangelos Terpos, Ioannis Ntanasis-Stathopoulos, Gerasimos-Petros Papassotiriou, et al.
American Journal of Hematology|December 29, 2018
Consolidation therapy with the combination of bortezomib and lenalidomide (VR) without dexamethasone in multiple myeloma patients after transplant: Effects on survival and bone outcomes in the absence of bisphosphonatesEvangelos Terpos, Efstathios Kastritis, Ioannis Ntanasis-Stathopoulos, et al.
Annals of Hematology|March 6, 2019
Pulmonary function abnormalities are common in patients with multiple myeloma and are independently associated with worse outcomeGeorgia Trakada, Efstathios Kastritis, Maria Gavriatopoulou, et al.
Blood Cancer Journal|November 5, 2020
Carfilzomib-associated renal toxicity is common and unpredictable: a comprehensive analysis of 114 multiple myeloma patientsDespina Fotiou, Maria Roussou, Charikleia Gakiopoulou, et al.
Journal of Clinical Medicine|June 10, 2022
Newly Diagnosed Multiple Myeloma Patients with Skeletal-Related Events and Abnormal MRI Pattern Have Poor Survival Outcomes: A Prospective Study on 370 PatientsNikolaos Kanellias, Ioannis Ntanasis-Stathopoulos, Maria Gavriatopoulou, et al.
Leukemia|July 21, 2018
Detection of MYD88 and CXCR4 mutations in cell-free DNA of patients with IgM monoclonal gammopathiesTina Bagratuni, Ioannis Ntanasis-Stathopoulos, Maria Gavriatopoulou, et al.
American Journal of Hematology|June 22, 2022
Chromosome 1q21 aberrations identify ultra high-risk myeloma with prognostic and clinical implicationsEfstathios Kastritis, Magdalini Migkou, Dimitra Dalampira, et al.
Blood Advances|January 4, 2018
Cardiac and renal complications of carfilzomib in patients with multiple myelomaMeletios A Dimopoulos, Maria Roussou, Maria Gavriatopoulou, et al.
Pageof 8

Showing results (41-50 of 71) with videos related to

Sort By:
Pageof 8
Leukemia & Lymphoma|January 11, 2019
Vulnerability variables among octogenerian myeloma patients: a single-center analysis of 110 patientsMaria Gavriatopoulou, Despina Fotiou, Ursula Koloventzou, et al.
Diseases (Basel, Switzerland)|September 27, 2023
Tixagevimab/Cilgavimab as Pre-Exposure Prophylaxis against COVID-19 for Multiple Myeloma Patients: A Prospective Study in the Omicron EraIoannis Ntanasis-Stathopoulos, Charalampos Filippatos, Maria Gavriatopoulou, et al.
Journal of Clinical Medicine|October 7, 2020
Circulating Soluble Urokinase-Type Plasminogen Activator Receptor Levels Reflect Renal Function in Newly Diagnosed Patients with Multiple Myeloma Treated with Bortezomib-Based InductionEvangelos Terpos, Ioannis Ntanasis-Stathopoulos, Gerasimos-Petros Papassotiriou, et al.
American Journal of Hematology|December 29, 2018
Consolidation therapy with the combination of bortezomib and lenalidomide (VR) without dexamethasone in multiple myeloma patients after transplant: Effects on survival and bone outcomes in the absence of bisphosphonatesEvangelos Terpos, Efstathios Kastritis, Ioannis Ntanasis-Stathopoulos, et al.
Annals of Hematology|March 6, 2019
Pulmonary function abnormalities are common in patients with multiple myeloma and are independently associated with worse outcomeGeorgia Trakada, Efstathios Kastritis, Maria Gavriatopoulou, et al.
Blood Cancer Journal|November 5, 2020
Carfilzomib-associated renal toxicity is common and unpredictable: a comprehensive analysis of 114 multiple myeloma patientsDespina Fotiou, Maria Roussou, Charikleia Gakiopoulou, et al.
Journal of Clinical Medicine|June 10, 2022
Newly Diagnosed Multiple Myeloma Patients with Skeletal-Related Events and Abnormal MRI Pattern Have Poor Survival Outcomes: A Prospective Study on 370 PatientsNikolaos Kanellias, Ioannis Ntanasis-Stathopoulos, Maria Gavriatopoulou, et al.
Leukemia|July 21, 2018
Detection of MYD88 and CXCR4 mutations in cell-free DNA of patients with IgM monoclonal gammopathiesTina Bagratuni, Ioannis Ntanasis-Stathopoulos, Maria Gavriatopoulou, et al.
American Journal of Hematology|June 22, 2022
Chromosome 1q21 aberrations identify ultra high-risk myeloma with prognostic and clinical implicationsEfstathios Kastritis, Magdalini Migkou, Dimitra Dalampira, et al.
Blood Advances|January 4, 2018
Cardiac and renal complications of carfilzomib in patients with multiple myelomaMeletios A Dimopoulos, Maria Roussou, Maria Gavriatopoulou, et al.
Pageof 8